Key facts
- Rhelixa’s last known valuation is $17.2M.
- It has raised $5.5M; the latest was Later Stage VC ($3.3M) in Aug 2024.
- Notable investors include Global Brain, Daiwa Corporate Investment, Leave a Nest Capital, Sompo Japan Insurance, Capital Medica Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Rhelixa
- ·The full record, as it builds
Funding rounds
No funding rounds for Rhelixa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rhelixa
Developer of epigenome analysis technology designed to improve the efficiency and accuracy of life science research and development. The company's technology offers a wide range of solutions, including consulting on experimental design, biological interpretation discovery, thesis writing, and research and development support, enabling clients to optimize efficiency and accuracy in their operations.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2015
- Employees
- 47
- Website
- rhelixa.com/
- Ownership
- Privately Held (backing)
Rhelixa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rhelixa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rhelixa in its N-PORT filings yet. We sweep new filings monthly.